{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,24]],"date-time":"2025-06-24T04:07:59Z","timestamp":1750738079247,"version":"3.41.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,6,23]]},"DOI":"10.7759\/cureus.86621","type":"journal-article","created":{"date-parts":[[2025,6,23]],"date-time":"2025-06-23T23:57:17Z","timestamp":1750723037000},"source":"Crossref","is-referenced-by-count":0,"title":["An Atypical Presentation of Thyroid Eye Disease in a Patient With a Remote History of Graves\u2019 Disease"],"prefix":"10.7759","author":[{"given":"Nancy L","family":"Van Buren","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caroline Y","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth A","family":"Bradley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra0905750","article-title":"Graves' ophthalmopathy","volume":"362","author":"Bahn RS","year":"2010","unstructured":"Bahn RS. Graves' ophthalmopathy. N Engl J Med. 2010, 362:726-38. 10.1056\/NEJMra0905750","journal-title":"N Engl J Med"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1007\/s40618-020-01380-9","article-title":"Thyrotropin receptor antibodies and Graves' orbitopathy","volume":"44","author":"Diana T","year":"2021","unstructured":"Diana T, Ponto KA, Kahaly GJ. Thyrotropin receptor antibodies and Graves' orbitopathy. J Endocrinol Invest. 2021, 44:703-12. 10.1007\/s40618-020-01380-9","journal-title":"J Endocrinol Invest"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2012-3873","article-title":"Prevalence and natural history of Graves' orbitopathy in a large series of patients with newly diagnosed graves' hyperthyroidism seen at a single center","volume":"98","author":"Tanda ML","year":"2013","unstructured":"Tanda ML, Piantanida E, Liparulo L, et al.. Prevalence and natural history of Graves' orbitopathy in a large series of patients with newly diagnosed graves' hyperthyroidism seen at a single center. J Clin Endocrinol Metab. 2013, 98:1443-9. 10.1210\/jc.2012-3873","journal-title":"J Clin Endocrinol Metab"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1007\/s40618-019-01141-3","article-title":"Orbital diseases mimicking graves' orbitopathy: a long-standing challenge in differential diagnosis","volume":"43","author":"Marin\u00f2 M","year":"2020","unstructured":"Marin\u00f2 M, Ionni I, Lanzolla G, Sframeli A, Latrofa F, Rocchi R, Marcocci C. Orbital diseases mimicking graves' orbitopathy: a long-standing challenge in differential diagnosis. J Endocrinol Invest. 2020, 43:401-11. 10.1007\/s40618-019-01141-3","journal-title":"J Endocrinol Invest"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.2147\/opth.s5228","article-title":"Update on thyroid eye disease and management","volume":"3","author":"Bothun ED","year":"2009","unstructured":"Bothun ED, Scheurer RA, Harrison AR, Lee MS. Update on thyroid eye disease and management. Clin Ophthalmol. 2009, 3:543-51. 10.2147\/opth.s5228","journal-title":"Clin Ophthalmol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1097\/IOP.0000000000001942","article-title":"The \"Quiet TED\"- a special subgroup of thyroid eye disease","volume":"37","author":"I\u00f1iguez-Ariza NM","year":"2021","unstructured":"I\u00f1iguez-Ariza NM, Sharma A, Garrity JA, Stan MN. The \"Quiet TED\"- a special subgroup of thyroid eye disease. Ophthalmic Plast Reconstr Surg. 2021, 37:551-5. 10.1097\/IOP.0000000000001942","journal-title":"Ophthalmic Plast Reconstr Surg"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1038\/s41433-018-0242-9","article-title":"Serial TSH-receptor antibody levels to guide the management of thyroid eye disease: the impact of smoking, immunosuppression, radio-iodine, and thyroidectomy","volume":"33","author":"Roos JC","year":"2019","unstructured":"Roos JC, Paulpandian V, Murthy R. Serial TSH-receptor antibody levels to guide the management of thyroid eye disease: the impact of smoking, immunosuppression, radio-iodine, and thyroidectomy. Eye (Lond). 2019, 33:212-7. 10.1038\/s41433-018-0242-9","journal-title":"Eye (Lond)"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-023-01510-4","article-title":"CD4(+) T cell memory","volume":"24","author":"K\u00fcnzli M","year":"2023","unstructured":"K\u00fcnzli M, Masopust D. CD4(+) T cell memory. Nat Immunol. 2023, 24:903-14. 10.1038\/s41590-023-01510-4","journal-title":"Nat Immunol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.45907","article-title":"Atypical asymmetric presentation of severe Graves\u2019 orbitopathy","volume":"15","author":"Gupta P","year":"2023","unstructured":"Gupta P, Kaur N, Goyal A, Aggarwal A. Atypical asymmetric presentation of severe Graves\u2019 orbitopathy. Cureus. 2023, 15:45907. 10.7759\/cureus.45907","journal-title":"Cureus"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1007\/s40123-022-00467-1","article-title":"Correction to: quality of life in patients with chronic thyroid eye disease in the United States","volume":"11","author":"Cockerham KP","year":"2022","unstructured":"Cockerham KP, Padnick-Silver L, Stuertz N, Francis-Sedlak M, Holt RJ. Correction to: quality of life in patients with chronic thyroid eye disease in the United States. Ophthalmol Ther. 2022, 11:923. 10.1007\/s40123-022-00467-1","journal-title":"Ophthalmol Ther"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2010.1634","article-title":"Risk factors for development or deterioration of Graves' ophthalmopathy","volume":"20","author":"Stan MN","year":"2010","unstructured":"Stan MN, Bahn RS. Risk factors for development or deterioration of Graves' ophthalmopathy. Thyroid. 2010, 20:777-83. 10.1089\/thy.2010.1634","journal-title":"Thyroid"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.eprac.2020.11.011","article-title":"Risk factors of thyroid eye disease","volume":"27","author":"Lee MH","year":"2021","unstructured":"Lee MH, Chin YH, Ng CH, et al.. Risk factors of thyroid eye disease. Endocr Pract. 2021, 27:245-53. 10.1016\/j.eprac.2020.11.011","journal-title":"Endocr Pract"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2015-4294","article-title":"Risk factors for Graves\u2019 orbitopathy; the Australian Thyroid-Associated Orbitopathy Research (ATOR) study","volume":"101","author":"Khong JJ","year":"2016","unstructured":"Khong JJ, Finch S, De Silva C, Rylander S, Craig JE, Selva D, Ebeling PR. Risk factors for Graves\u2019 orbitopathy; the Australian Thyroid-Associated Orbitopathy Research (ATOR) study. J Clin Endocrinol Metab. 2016, 101:2711-20. 10.1210\/jc.2015-4294","journal-title":"J Clin Endocrinol Metab"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-014-0289-8","article-title":"Stress triggers the onset and the recurrences of hyperthyroidism in patients with Graves' disease","volume":"48","author":"Vita R","year":"2015","unstructured":"Vita R, Lapa D, Trimarchi F, Benvenga S. Stress triggers the onset and the recurrences of hyperthyroidism in patients with Graves' disease. Endocrine. 2015, 48:254-63. 10.1007\/s12020-014-0289-8","journal-title":"Endocrine"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.3390\/v15030782","article-title":"The role of viral infections in the onset of autoimmune diseases","volume":"15","author":"Sundaresan B","year":"2023","unstructured":"Sundaresan B, Shirafkan F, Ripperger K, Rattay K. The role of viral infections in the onset of autoimmune diseases. Viruses. 2023, 15:782. 10.3390\/v15030782","journal-title":"Viruses"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-017-3748-9","article-title":"The autoimmune\/inflammatory syndrome induced by adjuvants (ASIA)\/Shoenfeld's syndrome: descriptive analysis of 300 patients from the international ASIA syndrome registry","volume":"37","author":"Watad A","year":"2018","unstructured":"Watad A, Quaresma M, Bragazzi NL, Cervera R, Tervaert JW, Amital H, Shoenfeld Y. The autoimmune\/inflammatory syndrome induced by adjuvants (ASIA)\/Shoenfeld's syndrome: descriptive analysis of 300 patients from the international ASIA syndrome registry. Clin Rheumatol. 2018, 37:483-93. 10.1007\/s10067-017-3748-9","journal-title":"Clin Rheumatol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines9050435","article-title":"Immune-mediated disease flares or new-onset disease in 27 subjects following mRNA\/DNA SARS-CoV-2 vaccination","volume":"9","author":"Watad A","year":"2021","unstructured":"Watad A, De Marco G, Mahajna H, et al.. Immune-mediated disease flares or new-onset disease in 27 subjects following mRNA\/DNA SARS-CoV-2 vaccination. Vaccines (Basel). 2021, 9:435. 10.3390\/vaccines9050435","journal-title":"Vaccines (Basel)"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1097\/IOP.0000000000002059","article-title":"Thyroid eye disease following COVID-19 vaccine in a patient with a history Graves\u2019 disease: a case report","volume":"37","author":"Rubinstein TJ","year":"2021","unstructured":"Rubinstein TJ. Thyroid eye disease following COVID-19 vaccine in a patient with a history Graves\u2019 disease: a case report. Ophthalmic Plast Reconstr Surg. 2021, 37:221-3. 10.1097\/IOP.0000000000002059","journal-title":"Ophthalmic Plast Reconstr Surg"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2021.0142","article-title":"Two cases of Graves\u2019 disease following SARS-CoV-2 vaccination: an autoimmune\/inflammatory syndrome induced by adjuvants","volume":"31","author":"Vera-Lastra O","year":"2021","unstructured":"Vera-Lastra O, Ordinola Navarro A, Cruz Domiguez MP, Medina G, S\u00e1nchez Valadez TI, Jara LJ. Two cases of Graves\u2019 disease following SARS-CoV-2 vaccination: an autoimmune\/inflammatory syndrome induced by adjuvants. Thyroid. 2021, 31:1436-9. 10.1089\/thy.2021.0142","journal-title":"Thyroid"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgad501","article-title":"Increased risk of thyroid eye disease following COVID-19 vaccination","volume":"109","author":"Muller I","year":"2024","unstructured":"Muller I, Consonni D, Crivicich E, Di Marco F, Curr\u00f2 N, Salvi M. Increased risk of thyroid eye disease following COVID-19 vaccination. J Clin Endocrinol Metab. 2024, 109:516-26. 10.1210\/clinem\/dgad501","journal-title":"J Clin Endocrinol Metab"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1097\/IOP.0000000000002367","article-title":"Alemtuzumab-induced thyroid eye disease: a comprehensive case series and review of the literature","volume":"39","author":"Nirmalan A","year":"2023","unstructured":"Nirmalan A, Blecher N, Hyder S, et al.. Alemtuzumab-induced thyroid eye disease: a comprehensive case series and review of the literature. Ophthalmic Plast Reconstr Surg. 2023, 39:470-4. 10.1097\/IOP.0000000000002367","journal-title":"Ophthalmic Plast Reconstr Surg"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1016\/j.eprac.2024.06.010","article-title":"Impact of teprotumumab on clinical practice in thyroid eye disease","volume":"30","author":"Rachmasari KN","year":"2024","unstructured":"Rachmasari KN, Toro-Tobon D, Wagner LH, Tooley AA, Bradley EA, Stan MN. Impact of teprotumumab on clinical practice in thyroid eye disease. Endocr Pract. 2024, 30:937-42. 10.1016\/j.eprac.2024.06.010","journal-title":"Endocr Pract"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1097\/IOP.0000000000000371","article-title":"Recurrent thyroid eye disease","volume":"31","author":"Patel P","year":"2015","unstructured":"Patel P, Khandji J, Kazim M. Recurrent thyroid eye disease. Ophthalmic Plast Reconstr Surg. 2015, 31:445-8. 10.1097\/IOP.0000000000000371","journal-title":"Ophthalmic Plast Reconstr Surg"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1210\/jcemcr\/luaf051","article-title":"Puzzling late relapse of thyroid eye disease: a case series","volume":"3","author":"Oustabassidis E","year":"2025","unstructured":"Oustabassidis E, Murphy N, Turner HE, Norris JH. Puzzling late relapse of thyroid eye disease: a case series. JCEM Case Rep. 2025, 3:051. 10.1210\/jcemcr\/luaf051","journal-title":"JCEM Case Rep"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1038\/sj.eye.6701396","article-title":"Late presentation of severe thyroid eye disease","volume":"18","author":"Manzouri B","year":"2004","unstructured":"Manzouri B, Bates A, Rose GE, Adams GG. Late presentation of severe thyroid eye disease. Eye (Lond). 2004, 18:1021-3. 10.1038\/sj.eye.6701396","journal-title":"Eye (Lond)"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgad538","article-title":"Outcomes of patients with Graves disease 25 years after initiating antithyroid drug therapy","volume":"109","author":"Meling Stokland AE","year":"2024","unstructured":"Meling Stokland AE, Austdal M, Nedreb\u00f8 BG, et al.. Outcomes of patients with Graves disease 25 years after initiating antithyroid drug therapy. J Clin Endocrinol Metab. 2024, 109:827-36. 10.1210\/clinem\/dgad538","journal-title":"J Clin Endocrinol Metab"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2022.0251","article-title":"Management of thyroid eye disease\u00a0: a consensus statement by the American Thyroid Association and the European Thyroid Association","volume":"32","author":"Burch HB","year":"2022","unstructured":"Burch HB, Perros P, Bednarczuk T, et al.. Management of thyroid eye disease\u00a0: a consensus statement by the American Thyroid Association and the European Thyroid Association. Thyroid. 2022, 32:1439-70. 10.1089\/thy.2022.0251","journal-title":"Thyroid"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1097\/ICU.0000000000000402","article-title":"Update on Graves disease: advances in treatment of mild, moderate and severe thyroid eye disease","volume":"28","author":"Strianese D","year":"2017","unstructured":"Strianese D. Update on Graves disease: advances in treatment of mild, moderate and severe thyroid eye disease. Curr Opin Ophthalmol. 2017, 28:505-13. 10.1097\/ICU.0000000000000402","journal-title":"Curr Opin Ophthalmol"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2023.0167","article-title":"Medical therapy in patients with moderate to severe, steroid-resistant, thyroid eye disease","volume":"33","author":"Toro-Tobon D","year":"2023","unstructured":"Toro-Tobon D, Rachmasari KN, Bradley EA, Wagner LH, Tooley AA, Stokken JK, Stan MN. Medical therapy in patients with moderate to severe, steroid-resistant, thyroid eye disease. Thyroid. 2023, 33:1237-44. 10.1089\/thy.2023.0167","journal-title":"Thyroid"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgaa646","article-title":"Management of graves thyroidal and extrathyroidal disease: an update","volume":"105","author":"Kahaly GJ","year":"2020","unstructured":"Kahaly GJ. Management of graves thyroidal and extrathyroidal disease: an update. J Clin Endocrinol Metab. 2020, 105:3704-20. 10.1210\/clinem\/dgaa646","journal-title":"J Clin Endocrinol Metab"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-020-01287-y","article-title":"Teprotumumab: first approval","volume":"80","author":"Markham A","year":"2020","unstructured":"Markham A. Teprotumumab: first approval. Drugs. 2020, 80:509-12. 10.1007\/s40265-020-01287-y","journal-title":"Drugs"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1910434","article-title":"Teprotumumab for the treatment of active thyroid eye disease","volume":"382","author":"Douglas RS","year":"2020","unstructured":"Douglas RS, Kahaly GJ, Patel A, et al.. Teprotumumab for the treatment of active thyroid eye disease. N Engl J Med. 2020, 382:341-52. 10.1056\/NEJMoa1910434","journal-title":"N Engl J Med"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2021.03.006","article-title":"A perspective on the current role of teprotumumab in treatment of thyroid eye disease","volume":"128","author":"Allen RC","year":"2021","unstructured":"Allen RC, Bradley EA, Fante RG, Lucarelli MJ. A perspective on the current role of teprotumumab in treatment of thyroid eye disease. Ophthalmology. 2021, 128:1125-8. 10.1016\/j.ophtha.2021.03.006","journal-title":"Ophthalmology"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2002754","article-title":"Teprotumumab for active thyroid eye disease","volume":"382","author":"Kim S","year":"2020","unstructured":"Kim S, Patzek S. Teprotumumab for active thyroid eye disease. N Engl J Med. 2020, 382:1958-9. 10.1056\/NEJMc2002754","journal-title":"N Engl J Med"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1097\/NAN.0000000000000446","article-title":"Infusion center guidelines for teprotumumab infusions: informed consent, safety, and management of side effects","volume":"44","author":"Kang J","year":"2021","unstructured":"Kang J, Lechuga M, Braun J, Kossler A, Douglas R, Cockerham K. Infusion center guidelines for teprotumumab infusions: informed consent, safety, and management of side effects. J Infus Nurs. 2021, 44:331-8. 10.1097\/NAN.0000000000000446","journal-title":"J Infus Nurs"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajoc.2022.101484","article-title":"Teprotumumab in advanced reactivated thyroid eye disease","volume":"26","author":"Cheng OT","year":"2022","unstructured":"Cheng OT, Schlachter DM. Teprotumumab in advanced reactivated thyroid eye disease. Am J Ophthalmol Case Rep. 2022, 26:101484. 10.1016\/j.ajoc.2022.101484","journal-title":"Am J Ophthalmol Case Rep"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1038\/s41433-024-02967-9","article-title":"The changing landscape of thyroid eye disease: current clinical advances and future outlook","volume":"38","author":"Moledina M","year":"2024","unstructured":"Moledina M, Damato EM, Lee V. The changing landscape of thyroid eye disease: current clinical advances and future outlook. Eye (Lond). 2024, 38:1425-37. 10.1038\/s41433-024-02967-9","journal-title":"Eye (Lond)"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgad381","article-title":"Proof-of-concept and randomized, placebo-controlled trials of an FcRn inhibitor, batoclimab, for thyroid eye disease","volume":"108","author":"Kahaly GJ","year":"2023","unstructured":"Kahaly GJ, Dolman PJ, Wolf J, et al.. Proof-of-concept and randomized, placebo-controlled trials of an FcRn inhibitor, batoclimab, for thyroid eye disease. J Clin Endocrinol Metab. 2023, 108:3122-34. 10.1210\/clinem\/dgad381","journal-title":"J Clin Endocrinol Metab"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1177\/11206721221083836","article-title":"Outcomes and risk factors of surgical management of thyroid eye disease-related diplopia","volume":"32","author":"Laezza MP","year":"2022","unstructured":"Laezza MP, Concilio M, Giordano M, Lanni V, Iuliano A, Strianese D. Outcomes and risk factors of surgical management of thyroid eye disease-related diplopia. Eur J Ophthalmol. 2022, 32:3679-84. 10.1177\/11206721221083836","journal-title":"Eur J Ophthalmol"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1038\/eye.2017.260","article-title":"Orbital decompression for thyroid eye disease: methods, outcomes, and complications","volume":"32","author":"Jefferis JM","year":"2018","unstructured":"Jefferis JM, Jones RK, Currie ZI, Tan JH, Salvi SM. Orbital decompression for thyroid eye disease: methods, outcomes, and complications. Eye (Lond). 2018, 32:626-36. 10.1038\/eye.2017.260","journal-title":"Eye (Lond)"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/375894-an-atypical-presentation-of-thyroid-eye-disease-in-a-patient-with-a-remote-history-of-graves-disease","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,23]],"date-time":"2025-06-23T23:57:17Z","timestamp":1750723037000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/375894-an-atypical-presentation-of-thyroid-eye-disease-in-a-patient-with-a-remote-history-of-graves-disease"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,23]]},"references-count":40,"URL":"https:\/\/doi.org\/10.7759\/cureus.86621","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6,23]]}}}